Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B vs Engerix-B in Healthy Adults 40-70 Years
NCT01005407Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Feb 2010
- Primary completion
- Jan 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
A Phase 3 trial of Heplisav-B in hepatitis B (HBV), sponsored by Dynavax Technologies. Started Feb 2010; status: completed.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01005407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005407.